Eliana Merle
Stock Analyst at UBS
(3.95)
# 612
Out of 5,133 analysts
90
Total ratings
52.24%
Success rate
11.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Assumes: Neutral | $40 → $34 | $39.60 | -14.14% | 9 | Jan 7, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $79.11 | +3.65% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $2.66 | +238.35% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $4.01 | +498.50% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $34.11 | -73.61% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $493.90 | +5.89% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $48.13 | -58.44% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $215.19 | +42.66% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $55.20 | +106.52% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $369.96 | +48.66% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $21.46 | -44.08% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.29 | +249.34% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.29 | +70.87% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $74.21 | -5.67% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $21.33 | +106.28% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $3.48 | -36.78% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $119.95 | -40.81% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $28.81 | -2.81% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.21 | +93.24% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $5.71 | -47.46% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $107.19 | +22.21% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $28.32 | -82.34% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $34.45 | -47.75% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $21.50 | +95.35% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $23.99 | -8.30% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $15.05 | +212.29% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.32 | +11.73% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $33.25 | +303.07% | 3 | Aug 19, 2020 |
Moderna
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $39.60
Upside: -14.14%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $79.11
Upside: +3.65%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $2.66
Upside: +238.35%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $4.01
Upside: +498.50%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $34.11
Upside: -73.61%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $493.90
Upside: +5.89%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $48.13
Upside: -58.44%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $215.19
Upside: +42.66%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $55.20
Upside: +106.52%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $369.96
Upside: +48.66%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $21.46
Upside: -44.08%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.29
Upside: +249.34%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.29
Upside: +70.87%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $74.21
Upside: -5.67%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $21.33
Upside: +106.28%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $3.48
Upside: -36.78%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $119.95
Upside: -40.81%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $28.81
Upside: -2.81%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.21
Upside: +93.24%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $5.71
Upside: -47.46%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $107.19
Upside: +22.21%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $28.32
Upside: -82.34%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $34.45
Upside: -47.75%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $21.50
Upside: +95.35%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $23.99
Upside: -8.30%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $15.05
Upside: +212.29%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.32
Upside: +11.73%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $33.25
Upside: +303.07%